Showing 8201-8210 of 8647 results for "".
- Biophytis Files Registration Statement for Proposed Initial Public Offering in the United Stateshttps://modernod.com/news/biophytis-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/2476604/Biophytis announced that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) in relation to a proposed initial public offering of American Depositary Shares representing ordinary shares of Biophytis. Biophytis has applied to list its shares
- NTC Grants Further License and Distribution Rights to Santen for Its Fixed Combination Dexamethasone With Levofloxacinhttps://modernod.com/news/ntc-grants-further-license-and-distribution-rights-to-santen-for-its-fixed-combination-dexamethasone-with-levofloxacin-in-south-east-asia/2476602/Italy-based NTC Srl and Santen Pharmaceutical announced an extension of their original agreement for Europe granting NTC’s license and distribution rights of levofloxacin+dexamethasone fixed combination eye drops to Santen. The countries covered by the exten
- Ocular Therapeutix OTX-TP Intracanalicular Insert Fails to Meet Phase 3 Endpointhttps://modernod.com/news/ocular-therapeutix-otx-tp-intracanalicular-insert-fails-to-meet-phase-3-endpoint/2476598/Ocular Therapeutix’s intracanalicular insert failed to meet its primary endpoint of statistically significant superiority in mean reduction of IOP compared with placebo at all nine time points, according to a company news release. OTX-TP is an intracanalicular insert that delivers a
- Evaluation of a Remote Diagnosis Imaging Model vs Dilated Eye Examination in Referable Macular Degenerationhttps://modernod.com/news/evaluation-of-a-remote-diagnosis-imaging-model-vs-dilated-eye-examination-in-referable-macular-degeneration/2476596/Researchers examined if the identification of referable macular degeneration could be done using the remote diagnosis imaging model as a clinical screening tool. They conducted a nonrandomized study of 159 patients in facilities with high rates of diabetic retinopathy and age-related macular dege
- Neuropathy May Drive Dry Eye in Migraine Patientshttps://modernod.com/news/neuropathy-may-drive-dry-eye-in-migraine-patients/2476593/Migraine patients with dry eye are more likely to have symptoms suggestive of neuropathy than dry eye patients who don’t have migraines, according to new findings, as reported by Reuters Health. The results raise the possibil
- FDA OKs IncobotulinumtoxinA (Xeomin) First-Line in Blepharospasmhttps://modernod.com/news/fda-oks-incobotulinumtoxina-xeomin-first-line-in-blepharospasm/2476587/The FDA has approved broadening the indication for incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals) as first-line therapy for blepharospasm in adult patients, the manufacturer has announced, as reported in Medscape. Beni
- Cholesterol-Lowering Drugs Tied to Reduced Glaucoma Riskhttps://modernod.com/news/cholesterol-lowering-drugs-tied-to-reduced-glaucoma-risk/2476570/High cholesterol is associated with an increased risk of developing glaucoma, but a new study suggests taking statins to lower cholesterol helps to reduce this risk, according to a Reuters
- Genentech: Pivotal Phase 3 Data for Neuromyelitis Optica Spectrum Disorder (Devic’s Disease)https://modernod.com/news/genentech-pivotal-phase-3-data-for-neuromyelitis-optica-spectrum-disorder-devics-disease/2476566/Genentech presented new pivotal phase 3 data for the rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), also known as Devic’s Disease, for which there are no approved treatments. NMOSD is a rare, lifelong and debilitating autoimmune disease of the c
- Pentosan Polysulfate Sodium Treatment Strongly Linked With Maculopathy and Vision Losshttps://modernod.com/news/pentosan-polysulfate-sodium-treatment-strongly-linked-with-maculopathy-and-vision-loss/2476563/Patients taking pentosan polysulfate sodium (PPS), which has been on the market for many years, appear to be at greater risk for a newly described maculopathy and vision loss, researchers report, according to Reuters. “Exposu
- Mati Therapeutics Phase 2 Nepafenac Evolute Clinical Trial Results Show Significant Postoperative Pain Reductionhttps://modernod.com/news/mati-therapeutics-phase-2-nepafenac-evolute-clinical-trial-results-show-significant-postoperative-pain-reduction/2476558/Mati Therapeutics announced that it has completed a phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute sustained ocular punctal plug drug delivery platform. The trial was a multicenter, randomized, masked evaluation of Nepafenac Evolute